2015 - 2016

Categories:History
Author:
Origin:
Time of issue:2016-03-09
Views:0

(Summary description)
◆ Winning support from the national major special fund duringthe12th Five-Year period for the project initialization of a Class 1 new drug, and the project was completed without any defects.
◆ Submittingapplications for clinical trials of severalClass3.1 new drugs.

2015 - 2016

(Summary description)
◆ Winning support from the national major special fund duringthe12th Five-Year period for the project initialization of a Class 1 new drug, and the project was completed without any defects.
◆ Submittingapplications for clinical trials of severalClass3.1 new drugs.

Categories:History
Author:
Origin:
Time of issue:2016-03-09
Views:0

Early Achievements

Previous: 2016 - 2018

Next: 2013 - 2015

Previous: 2016 - 2018

Next: 2013 - 2015

New Information | Series C financing of over 100 million yuan marks the first round of financing for Shengshi Taike, paving the way for commercialization of core innovative products

2024-09-04

Dr. Wang Tong, Chief Scientific Officer of Shengshi Taike, has been selected as a "Double Innovation Talent" in Jiangsu Province

Recently, the "Double Innovation Talent Plan" organized by the Jiangsu Provincial People's Government and the Provincial Talent Office was awarded a certificate of selection, and Dr. Wang Tong, Chief Scientific Officer of Shengshi Taike, was selected for the "2023 Jiangsu Province High level Innovation and Entrepreneurship Talent Introduction Plan". The Shengshi Taike R&D team led by Dr. Wang Tong is committed to the development of high-quality and differentiated small molecule innovative drugs, aiming to address major clinical pain points in the fields of blood sugar reduction, anti-tumor, and autoimmune diseases.

2024-07-31